ArticlePloS one2016
Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014).
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China.Digestive diseases and sciences · 2022Trial
- Levofloxacin and Rifampin Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- Multiplex PCR-Mass Spectrometry Mini-Sequencing Technology Detected Antibiotic Resistance ofInternational journal of molecular sciences · 2025Article
- Helicobacter pylori Infection in Colombia: Phylogeny, Resistome, and Virulome.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Article
- Antimicrobial susceptibility of clinicalMicrobiology spectrum · 2024Article
- Article
- Molecular tools of antibiotic resistance forFrontiers in gastroenterology (Lausanne, Switzerland) · 2024Review
- TheFrontiers in microbiology · 2023Article
- Antibiotic resistance ofFrontiers in cellular and infection microbiology · 2023Article
- Therapeutic Potential of Sitafloxacin as a New Drug Candidate forAntibiotics (Basel, Switzerland) · 2021Article
- Prevalence of Helicobacter pylori Antimicrobial Resistance Among Chilean Patients.Archives of medical research · 2021Article
- Whole-Genome Sequencing and Comparative Genomics of ThreePathogens (Basel, Switzerland) · 2021Article
- A comparative whole genome analysis of Helicobacter pylori from a human dense South Asian setting.Helicobacter · 2021Article
- A retrospective study of the antibiotic-resistant phenotypes and genotypes ofAmerican journal of cancer research · 2021Article
- Update on quinolone-containing rescue therapies forWorld journal of gastroenterology · 2020Review
- Reevaluation of the Efficacy of First Line Regimen forClinical and experimental gastroenterology · 2020Article
- High Prevalence of Antibiotic Resistance in IranianJournal of clinical medicine · 2019Article
- The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer.BMC microbiology · 2019Article
- Point Mutations atThe American journal of tropical medicine and hygiene · 2018Article
- [First-Line Eradication ofActa gastroenterologica LatinoamericanaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Increased resistance of Helicobacter pylori to clarithromycin and metronidazole has resulted in recommendation to substitute fluoroquinolones for eradication therapy. The aims of the study were to determine the prevalence and changes in primary levofloxacin resistance related to H. pylori gyrA sequences. The study utilized H. pylori strains isolated from patients undergoing gastroscopy in Bogotá, Colombia from 2009 to 2014. Levofloxacin susceptibility was assessed by agar dilution. Mutations in gyrA sequences affecting the quinolone resistance-determining region (QRDR) were evaluated by direct sequencing. Overall, the mean prevalence of primary levofloxacin resistance was 18.2% (80 of 439 samples). Resistance increased from 11.8% (12/102) in 2009 to 27.3% (21/77) in 2014 (p = 0.001). gyrA mutations in levofloxacin resistant strains were present in QRDR positions 87 and 91. The most common mutation was N87I (43.8%, 35/80) followed by D91N (28.8%, 23/80) and N87K (11.3%, 9/80). Levofloxacin resistance increased markedly in Colombia during the six-year study period. Primary levofloxacin resistance was most often mediated by point mutations in gyrA, with N87I being the most common QRDR mutation related to levofloxacin resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.